<DOC>
	<DOCNO>NCT01276067</DOCNO>
	<brief_summary>This open label , balance , randomize , two-treatment , two-period , two-sequence , single dose crossover study conduct compare relative bioavailability equal dose test reference product fast condition .</brief_summary>
	<brief_title>Bioequivalence Study Donepezil Hydrochloride 10 mg Tablets Under Fasting Conditions</brief_title>
	<detailed_description>This open label , balance , randomize , two-treatment , two-period , two-sequence , single dose crossover study conduct compare relative bioavailability equal dose test reference product fast condition . The study conduct 32 ( 31 complete ) healthy adult accordance Protocol No . 10940307 ( Revision 0 ) . In study period , single 10 mg tablet donepezil hydrochloride administer subject follow overnight fast least 10 hour . The test formulation donepezil hydrochloride 10 mg tablet ( OHM Laboratories , Inc. , USA subsidiary Ranbaxy Pharmaceuticals , Inc. USA ) reference formulation ARICEPT® ( donepezil hydrochloride ) 10 mg Tablets ( Eisai Inc. ) . The subject receive test product one study period reference product period ; order administration accord dose randomization schedule . Subjects confine clinical facility least 10 hour prior dose 24 hour blood collection . Subjects return clinical facility 36 , 48 , 72 hour blood sample collection . There 28-day interval treatment . Blood sample collect pre-dose interval 72 hour dose period . The plasma sample subject ship Warnex Bioanalytical Services determination donepezil concentration . Statistical analysis perform Ranbaxy Laboratories Limited compare bioequivalence test formulation reference product . Bioequivalence determine base confidence interval major pharmacokinetic parameter , AUC0-72 Cmax , donepezil .</detailed_description>
	<mesh_term>Donepezil</mesh_term>
	<criteria>1 . Males female , 18 65 year age ( inclusive ) Body Mass Index ( BMI ) 18 30 kg/m² inclusive . BMI calculate use Novum Pharmaceutical Research Services Standard Operating Procedures . 2 . Female subject child bear potential must either abstain sexual intercourse , use reliable nonhormonal method contraception ( e.g . condom spermicide , IUD ) least 30 day prior dose duration study . The use type hormonal contraception allow 3 . Good health determine lack clinically significant abnormality health assessment perform screen . 4 . Signed date informed consent form , meet criteria current FDA regulation . 1 . Females pregnant , lactate likely become pregnant study . 2 . History allergy sensitivity donepezil , cholinesterase inhibitor , history drug hypersensitivity intolerance , opinion Investigator , would compromise safety subject study 3 . Significant history current evidence chronic infectious disease , system disorder organ dysfunction . 4 . Presence gastrointestinal disease history malabsorption within last year . Any history gastrointestinal ulcer , bleed obstruction . 5 . History asthma obstructive pulmonary disease . 6 . History psychiatric disorder occur within last two year require hospitalization medication . 7 . Presence medical condition require regular treatment prescription drug ( include hormonal contraceptive ) . 8 . Use pharmacologic agent know significantly induce inhibit drugmetabolizing enzyme within 30 day prior dose . 9 . Receipt drug part research study within 30 day prior dose . 10 . Drug alcohol addiction require treatment past 12 month . 11 . Donation significant loss whole blood ( 480 ml ) within 30 day plasma within 14 day prior dose . 12 . Positive test result HIV , Hepatitis B surface antigen Hepatitis C antibody . 13 . Positive test result drug abuse alcohol screening . 14 . Positive serum pregnancy test .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>